tetano
Editor, Senior Moderator
Virol J
. 2020 Oct 23;17(1):162.
doi: 10.1186/s12985-020-01428-5.
Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series
Wei Gao[SUP] 1 [/SUP], Si Chen[SUP] 1 [/SUP], Kun Wang[SUP] 1 [/SUP], Rongzhang Chen[SUP] 1 [/SUP], Qian Guo[SUP] 1 [/SUP], Jingjing Lu[SUP] 1 [/SUP], Xiaodong Wu[SUP] 1 [/SUP], Yanan He[SUP] 1 [/SUP], Qiaoyun Yan[SUP] 1 [/SUP], Shengyun Wang[SUP] 2 [/SUP], Feilong Wang[SUP] 1 [/SUP], Li Jin[SUP] 1 [/SUP], Jing Hua[SUP] 3 [/SUP], Qiang Li[SUP] 4 [/SUP]
Affiliations
Abstract
Objective: We aimed to describe the features of 220 nonemergency (mild or common type) COVID-19 patients from a shelter hospital, as well as evaluate the efficiency of antiviral drug, Arbidol in their disease progressions.
Methods: Basic clinical characteristics were described and the efficacy of Arbidol was evaluated based on gender, age, maximum body temperature of the patients.
Results: Basically, males had a higher risk of fever and more onset symptoms than females. Arbidol could accelerate fever recovery and viral clearance in respiratory specimens, particularly in males. Arbidol also contributed to shorter hospital stay without obvious adverse reactions.
Conclusions: In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient's conditions. Arbidol showed several beneficial effects in these patients, especially in males. This study brought more researches enlightenment in understanding the emerging infectious disease.
Keywords: Arbidol; COVID-19; Coronavirus disease; Efficacy; SARS-CoV-2.
. 2020 Oct 23;17(1):162.
doi: 10.1186/s12985-020-01428-5.
Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series
Wei Gao[SUP] 1 [/SUP], Si Chen[SUP] 1 [/SUP], Kun Wang[SUP] 1 [/SUP], Rongzhang Chen[SUP] 1 [/SUP], Qian Guo[SUP] 1 [/SUP], Jingjing Lu[SUP] 1 [/SUP], Xiaodong Wu[SUP] 1 [/SUP], Yanan He[SUP] 1 [/SUP], Qiaoyun Yan[SUP] 1 [/SUP], Shengyun Wang[SUP] 2 [/SUP], Feilong Wang[SUP] 1 [/SUP], Li Jin[SUP] 1 [/SUP], Jing Hua[SUP] 3 [/SUP], Qiang Li[SUP] 4 [/SUP]
Affiliations
- PMID: 33097047
- DOI: 10.1186/s12985-020-01428-5
Abstract
Objective: We aimed to describe the features of 220 nonemergency (mild or common type) COVID-19 patients from a shelter hospital, as well as evaluate the efficiency of antiviral drug, Arbidol in their disease progressions.
Methods: Basic clinical characteristics were described and the efficacy of Arbidol was evaluated based on gender, age, maximum body temperature of the patients.
Results: Basically, males had a higher risk of fever and more onset symptoms than females. Arbidol could accelerate fever recovery and viral clearance in respiratory specimens, particularly in males. Arbidol also contributed to shorter hospital stay without obvious adverse reactions.
Conclusions: In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient's conditions. Arbidol showed several beneficial effects in these patients, especially in males. This study brought more researches enlightenment in understanding the emerging infectious disease.
Keywords: Arbidol; COVID-19; Coronavirus disease; Efficacy; SARS-CoV-2.